Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mesoblast
Marketing
Wegovy and Zepbound tipped to fuel $20B heart failure boom
Analysts expect launches of medicines including Lilly’s Zepbound and Novo's Wegovy to help add $20 billion to the value of the market in a decade.
Nick Paul Taylor
Jan 7, 2025 11:12am
After two rejections, FDA approves Mesoblast's cell therapy
Dec 19, 2024 11:24am
Mesoblast scores FDA committee's backing for cell therapy
Aug 14, 2020 8:36am
Mesoblast takes FDA flack over cell therapy data: documents
Aug 12, 2020 8:29am
Mesoblast reaches milestone on Temcell with Japan partner JCR
Sep 21, 2015 3:46am
